Myoadenylate deaminase

Myoadenylate Deaminase Deficiency (MADD), also known as Adenylate Deaminase Deficiency or AMP Deaminase Deficiency, is a metabolic disorder affecting the muscles. It is characterized by the absence or mutation of the enzyme myoadenylate deaminase, which plays a crucial role in the adenosine triphosphate (ATP) regeneration process within muscle cells. This condition can lead to muscle pain, fatigue, and occasionally cramps or stiffness following physical activity. The severity and onset of symptoms can vary widely among individuals.

Symptoms and Diagnosis

The primary symptoms associated with Myoadenylate Deaminase Deficiency include muscle pain, weakness, fatigue, and sometimes muscle cramps or stiffness after exercise. These symptoms are due to the accumulation of adenosine monophosphate (AMP) and a deficiency in inosine monophosphate (IMP), leading to an imbalance in energy use and recovery in muscle cells.

Diagnosis of MADD is often made through a muscle biopsy, where the activity of the myoadenylate deaminase enzyme is measured. Genetic testing can also identify mutations in the AMPD1 gene, which is responsible for encoding the enzyme.

Genetics

Myoadenylate Deaminase Deficiency is primarily caused by mutations in the AMPD1 gene. The condition is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder.

Treatment and Management

There is no cure for Myoadenylate Deaminase Deficiency, but symptoms can often be managed through lifestyle adjustments and symptom-based treatments. Avoiding strenuous exercise and adopting a balanced diet may help reduce symptoms. In some cases, supplements such as ribose, which may help in the regeneration of ATP, are suggested, although evidence of their effectiveness is limited.

Epidemiology

The prevalence of Myoadenylate Deaminase Deficiency is estimated to be approximately 1-2% in the general population, making it one of the more common metabolic muscle disorders. However, many individuals with the condition may be asymptomatic or have mild symptoms and therefore remain undiagnosed.

Research Directions

Research into Myoadenylate Deaminase Deficiency is ongoing, with studies focusing on understanding the genetic basis of the condition, developing more effective diagnostic methods, and exploring potential treatments. Advances in genetic research may offer new insights into managing and treating MADD in the future.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian